Estrigenix Therapeutics to Attend The Menopause Society Meeting

MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier organization for health professionals with an interest in the many issues affecting women as they approach menopause and beyond. In addition, Pauline Maki, PhD, Professor of Psychiatry, Psychology, and Obstetrics & Gynecology at UIC and Scientific Advisory Board member of Estrigenix Therapeutics, will be presenting on “Mood, Sleep and Cognitive Function”.

Estrigenix was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in menopausal women with fewer side effects than current hormone therapy (HT).

The dramatic decline in the production of estrogen during menopause often can result in hot flashes, sleep disruption, memory dysfunction, anxiety, and depression in many women. Although traditional HT addresses these symptoms, HT has associated risks for breast cancer and blood clots leading to stroke. For this reason, many OB/GYNs will not prescribe HT for the approximately 20% of menopausal women with a history of breast or uterine cancer or stroke.

Additionally, some women who are not in these high-risk categories avoid taking estrogen due to the perceived health risks.  Recent clinical and preclinical findings have demonstrated that the negative side effects of HTs may be due to activation of the alpha, but not beta, estrogen receptor isoform. Therefore, estrogen-based HT that selectively targets ER beta may avoid the health risks associated with ER alpha activation.

Estrigenix has developed novel highly selective ER beta agonists that, in preclinical testing,demonstrated that long-term ER beta activation can reduce hot flash-like symptoms and enhance spatial and object recognition memories in ovariectomized mice.  These highly selective ER beta agonists have the potential to serve as a safe alternative to HT for the over sixty million menopausal women in the US alone, 80% experience of whom experience symptoms including hot flashes and memory dysfunction.  “Having a treatment that addresses hot flashes and memory dysfunction, but avoids the potential risks associated with traditional hormone therapy, such as cancer and stroke, would provide significant benefits for women” explained Sem.

To learn more about Estrigenix and how its technology may help improve women’s quality of life, visit


About Estrigenix Therapeutics, Inc.

Estrigenix Therapeutics, Inc. is a Wisconsin-based, privately held pharmaceutical company leading the way in research and progress in estrogen biology. Estrigenix was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent symptoms of menopause, including hot flashes and dementia, with fewer side effects than current hormone therapies.

For more information and to learn how Estrigenix is pioneering the way in symptom prevention for menopausal women, visit

Safe Harbor Statement

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Estrigenix Therapeutics, Inc. plans, timelines, or presumptions of results for the Company’s lead compounds or planned development and testing. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on several assumptions concerning future events and are subject to several risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our development efforts, the fluctuation of global economic conditions, the impact of current or future pandemics on our clinical development and regulatory review and approvals and on the manufacturing and prescribing of our lead compound, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our products for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Estrigenix Therapeutics is a registered trademark of Estrigenix Therapeutics, Inc.